No FDA-approved sermorelin product is sold in the United States. At Longevity Benchmark, we verify claims like this against the regulator's own records. Geref entered the US market in 1997, but the FDA withdrew its approval in June 2009 for commercial reasons, not safety reasons. It is neither an approved drug nor a banned one.
Sermorelin acetate is a 29-amino-acid analog of growth hormone-releasing hormone (GHRH). Rather than injecting growth hormone itself, it signals the pituitary gland to release the growth hormone your body already makes. That mechanism is why it is marketed, and why its regulatory history deserves a close read.
The Verdict
The Regulatory History in Five Steps
Sermorelin's current status is the result of a commercial decision rather than a safety finding, and the sequence explains why the two common descriptions of it are both wrong. The table below follows the FDA's own record.
| When | What happened | What it meant |
|---|---|---|
| 1997 | Geref and Geref Diagnostic approved | Sermorelin acetate reaches the US market as a prescription product for diagnosing and treating growth hormone deficiency in children |
| December 2008 | EMD Serono asks for the applications to be withdrawn | EMD Serono requests withdrawal of both applications. The stated reason is commercial rather than a safety finding |
| June 2009 | FDA withdraws approval of New Drug Applications (NDAs) 19-863 and 20-443 | No FDA-approved sermorelin product remains on the US market from this point |
| March 2013 | Federal Register determination | FDA formally determines the products were not withdrawn for reasons of safety or effectiveness, which keeps the abbreviated application pathway open |
| Today | Available only as a compounded preparation | Supplied by compounding pharmacies against a patient-specific prescription, outside the FDA approval system |
Marketing copy leans hardest on the 2013 entry. A determination that a product was not withdrawn for reasons of safety or effectiveness is a procedural finding that permits abbreviated applications. Marketing copy sometimes presents it as an endorsement. It is not one, and it describes the 1997 pediatric product rather than anything being sold to adults now.
How Sermorelin Differs from Growth Hormone
Sermorelin acts one step upstream of growth hormone, and that step is the entire case made for it. Sermorelin acts on the pituitary, so whatever growth hormone follows is released in the body's own pulses and stays under the body's own feedback control. Injected growth hormone skips that layer entirely.
| What it is | How it works | What that changes | Regulatory position |
|---|---|---|---|
| Sermorelin (compounded) | A 29-amino-acid analog of growth hormone-releasing hormone. Signals the pituitary to release its own growth hormone | Release stays pulsatile and remains subject to the body's own feedback controls | No FDA-approved product exists, so no agency has reviewed the specific preparation you receive |
| Recombinant human growth hormone | The hormone itself, given directly | Bypasses pituitary signaling and the feedback that limits it | FDA-approved for defined indications. Distribution for anti-aging use is separately restricted under federal law |
A mechanism that preserves feedback is a reasonable thing to prefer. It is also a mechanistic argument rather than a demonstrated outcome, and the two get conflated routinely in this category. Preserved pulsatility explains why sermorelin might behave differently. It does not establish that it produces the benefits a program is selling.
What Compounded Supply Means for a Buyer
A compounded preparation is made by a pharmacy for an individual patient and has not been reviewed by the FDA for safety, effectiveness or manufacturing quality. Compounding exists for good reasons, including cases where an approved product is unavailable in the form a patient needs. With a compounded preparation, the pharmacy stands behind the vial. The FDA does not.
That makes the pharmacy a fair subject for questions. Potency and purity can vary between compounders, and the buyer has no approval file to fall back on. The regulatory position of peptides in compounding is also under active review rather than settled, which is why availability in this category has changed before. The FDA maintains both a 503A bulk drug substances list and a separate list of substances that may present significant safety risks. Those two pages carry the current position. Read them before committing to a year-long program.
Reported Sermorelin Side Effects and Clinical Trial Evidence
The most common sermorelin side effects documented in clinical trials are local injection reactions characterized by pain, swelling, or redness. These local reactions occurred in about one patient in six. According to the manufacturer labelling reproduced on RxList, of the 350 patients exposed to sermorelin during clinical trials, three discontinued therapy due to injection reactions. If you receive this medication, your injection site is where a treatment-related reaction is most likely to appear.
Other treatment-related adverse events had individual occurrence rates of less than 1 percent. The labelling names seven specific events in this category: headache, flushing, dysphagia, dizziness, hyperactivity, somnolence, and urticaria. The manufacturer documentation provides no separate incidence numbers or percentages for these symptoms, confirming only that each appeared in fewer than one in one hundred participants. In addition, the trial records note that no generalized allergic reactions to sermorelin have been reported. An absence of reports does not guarantee zero risk.
At Longevity Benchmark, we review original drug labelling to clarify what published evidence can and cannot tell you about current care. The adverse-event profile on the label comes entirely from clinical trials of the approved product that is no longer marketed in the United States. Sermorelin is supplied today by compounding pharmacies. That distinction matters. Historical trial data does not describe what a compounded preparation of uncertain purity, concentration, or sterility may do. If you experience an adverse reaction, the published labelling cannot tell you whether your symptoms came from the peptide or from the pharmacy preparation itself.
Discuss any unexpected symptoms with your prescribing clinician before making changes to your protocol. If you experience persistent pain, flushing, difficulty swallowing, or sudden dizziness, tell your doctor promptly so they can review your response. A clinician can evaluate your symptoms against your personal medical history, check the preparation details with the dispensing pharmacy, and decide whether therapy should proceed. You can review how prescribers assess alternative compounds in our guide on sermorelin vs ipamorelin or explore broader clinical protocols across our men's health section.
Who Should Not Consider This
Four groups have clear reasons to stay away.
- Anyone with an active malignancy. Approved growth hormone products carry contraindications for active malignancy on their FDA labels, and a compounded peptide acting on the same pathway does not remove that caution.
- Anyone who has not had a pituitary or endocrine workup, who is treating a presumed deficiency that has not been demonstrated.
- Anyone pregnant or breastfeeding. Approved growth hormone labels restrict use in pregnancy, and a compounded preparation carries no approval file to consult at all.
- Anyone whose complaint is fatigue, poor sleep or stalled body composition, which have more likely explanations that are measurable.
That fourth group has the most tractable problem. Our guides to low testosterone, home sleep apnea testing and the thyroid panel cover three of them. Each has a diagnostic test and an established treatment path. A compounded peptide has neither.
Tracking IGF-1 During Sermorelin Therapy
Clinics use an IGF-1 blood test to assess sermorelin therapy because measuring growth hormone directly yields little useful data. Growth hormone secretion is episodic and pulsatile, with a half-life of 20 to 25 minutes. Blood levels spike during exercise, deep sleep onset, and periods of falling glucose, so a single blood draw captures only a temporary peak or trough. In contrast, circulating IGF-1 binds to carrier proteins that extend its half-life to more than 12 hours. The liver produces IGF-1 in response to growth hormone, turning the peptide into a stable, integrated measure of total growth hormone exposure.
A laboratory cannot interpret an IGF-1 result against a single adult reference range. Concentrations peak during adolescence and drop steadily throughout adulthood, which is why commercial requisitions require the patient's age. Clinicians evaluate results against reference intervals adjusted for age and sex that apply specifically to the laboratory and assay used.
Serial monitoring requires sticking to one laboratory because measurements are not interchangeable across different testing platforms. Natural biological variation also complicates serial testing. In a study of 84 healthy volunteers measured two weeks apart, 46 participants had IGF-1 concentrations that varied by more than 10%. Twelve participants showed shifts greater than 20%, and 5 differed by more than 30%. That baseline fluctuation sets a floor for deciding whether an observed change reflects medication activity or routine measurement noise.
A shifting biomarker does not equal clinical improvement. While a rising IGF-1 reading indicates that the liver responded to growth hormone receptor stimulation, it does not demonstrate gains in lean mass, body composition, or sleep quality.
What Would Change Our Answer
Three developments would revise this page. A randomized trial in healthy adults measuring a real outcome, rather than an IGF-1 level, would move the evidence question that is currently open. An explicit FDA decision on sermorelin's status under section 503A, either way, would settle the supply position and give compounders a basis to work from. A new approved product, through the abbreviated pathway the 2013 determination preserved, would move it back inside the approval system entirely.
Until one of those happens, ask any clinic offering sermorelin therapy which adult trials it is relying on and which pharmacy compounds its supply. Those two answers tell you more about a program than any description of the mechanism will.
Frequently Asked Questions
Is sermorelin FDA approved?
No FDA-approved sermorelin product is on the US market. Sermorelin acetate was approved in 1997 and sold as Geref for diagnosing and treating growth hormone deficiency in children. EMD Serono asked for the applications to be withdrawn in December 2008 for commercial reasons, and the FDA withdrew approval of New Drug Applications 19-863 and 20-443 in June 2009. Anyone receiving sermorelin in the US today is receiving a compounded preparation, which is a different regulatory category from an approved drug. Both "sermorelin is FDA approved" and "sermorelin is banned" are wrong, and the accurate description sits between them.
What did the 2013 FDA determination find?
The FDA published a determination in the Federal Register that the Geref products were not withdrawn from sale for reasons of safety or effectiveness. That finding is procedural and it matters: it lets the agency approve abbreviated applications for these products, which it could not do if the original had been pulled over a safety problem. It is not a statement that sermorelin is effective for the uses it is marketed for now. A determination about why a product left the market says nothing about what it does in adults seeking body-composition or sleep benefits.
How does sermorelin differ from growth hormone injections?
Sermorelin is an analog of growth hormone-releasing hormone, so it signals the pituitary to release the growth hormone you already make. Recombinant human growth hormone is the hormone itself, delivered directly. The practical difference is feedback. Because sermorelin acts a step upstream, release stays pulsatile and remains subject to the body's own regulatory controls, whereas injected growth hormone does not. That distinction is the main argument made for sermorelin, and it is a mechanistic argument rather than an outcome one.
What does "compounded" mean for what I receive?
A compounded preparation is made by a pharmacy for a specific patient rather than manufactured and reviewed as an approved drug. The FDA has not evaluated that preparation for safety, effectiveness or manufacturing quality. Potency and purity vary between pharmacies. Compounding has a legitimate role, notably where an approved product does not exist in the needed form. It also means the quality control you are relying on is the pharmacy's rather than the agency's, which is a reasonable question to ask a prescriber directly.
Is the evidence for sermorelin in adults strong?
The approved indication was diagnosing and treating growth hormone deficiency in children, and the evidence supporting approval came from that population. The adult uses it is marketed for today are different: body composition, sleep quality, recovery. Those rest on a much thinner published base, and we are not aware of large randomized trials in healthy adults that establish them. A mechanism that is plausible is not the same as a benefit that has been measured. Anyone weighing this should ask a prescriber which trials in adults they are relying on, and what those trials measured.
Is sermorelin legal to prescribe in the United States?
Compounded sermorelin is dispensed against patient-specific prescriptions, and the regulatory position of peptides in compounding is under active FDA review rather than settled. The agency maintains lists of bulk drug substances for use in compounding under section 503A and a separate list of substances it has identified as possibly presenting significant safety risks. Those lists change, and its Pharmacy Compounding Advisory Committee has been considering peptides. Check the current FDA 503A bulk drug substances list for the position in force, because availability in this category has changed more than once.
What should I ask before starting a peptide program?
Ask four things before you start. Which pharmacy compounds the supply, and what purity and potency testing does it publish? Which trials in adults support the specific outcome being offered to you? What baseline labs get drawn first? And what does a full year cost rather than the first month? A program that cannot answer the second question is selling a mechanism. Our guide to how hormone clinics differ covers the same diligence for testosterone prescribing.
Related
- Signs of low testosterone: the workup that comes first
- Men's hormone panel: what a baseline should include
- TRT clinics compared: how prescribing and monitoring differ
- How long TRT takes to work: published timelines for a treatment that has them
- Rapamycin for longevity: another off-label longevity route
- Methodology: how sources are verified